This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

ELIXA Trial

The ELIXA trial assessed CV safety associated with lixisenatide versus placebo in >6000 patients with T2D and a recent acute coronary syndrome. 3 This module details the CV outcomes and safety results from the trial.

ELIXA Trial
Rate this content
  • ELIXA Trial
  • ELIXA: study design
  • ELIXA: baseline characteristics (1/2)
  • ELIXA: baseline characteristics (2/2)
  • ELIXA: renal function at baseline
See More
Do you want to go to the Presentation Builder section to create a new presentation?
Cancel Go
Cancel